Toll-Like Receptor Agonists: Not Just for Vaccines Anymore
The role of TLR agonists has expanded, and now the molecules can be found in a variety of non-vaccine therapeutics.
Novartis's Influenza Vaccine Program
The global head of technical operations at Novartis talks about new technologies for vaccine development and manufacturing.
Evolution of Live-Attenuated HIV Vaccines
Safety concerns remain for developing replicating vectors based on the pathogen human immunodeficiency virus type 1.
Virosomes: A Novel Strategy for Drug Delivery and Targeting
Virosomes present novel drug-delivery vehicles with distinct advantages over liposomes.
